Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One A Day Marketing Claims Spark Another CSPI-Bayer Face Off

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest threatens to sue if Bayer HealthCare does not discontinue claims that One A Day multivitamins “support” breast, heart, eye and bone health. CSPI argues the problem is rooted in linking legitimate claims to scientific research in a way that implies disease claims.

You may also be interested in...



CSPI Litigation Again Targets Bayer One A Day Claims

The proposed class-action complaint CSPI filed federal court marks the consumer advocacy group’s third allegation against claims for One A Day products. The complaint seeks an injunction against some claims and refunds to consumers who “purchased the products expecting the promised benefits,” CSPI says.

CSPI Litigation Again Targets Bayer One A Day Claims

The proposed class-action complaint CSPI filed federal court marks the consumer advocacy group’s third allegation against claims for One A Day products. The complaint seeks an injunction against some claims and refunds to consumers who “purchased the products expecting the promised benefits,” CSPI says.

Bayer Says One A Day Selenium Prostate Cancer Claims Are In Fair Play

Bayer asserts the prostate cancer risk reduction claims for its One A Day Men's multivitamin supplements are backed by an FDA-approved qualified health claim for selenium

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel